

5.1. „peer-reviewed” PubMed listed publications Author

1. Gridelli C, de Castro Carpeno J, Dingemans AC, **Griesinger F.**, Grossi F, Langer C, Ohe Y, Syrigos K, Thatcher N, Das-Gupta A, Truman M, Donica M, Smoljanovic V, Bennouna J. Safety and Efficacy of Bevacizumab Plus Standard-of-Care Treatment Beyond Disease Progression in Patients With Advanced Non-Small Cell Lung Cancer: The AvaALL Randomized Clinical Trial. *JAMA Oncol.* 2018 Aug 30:e183486. doi: 10.1001/jamaoncol.2018.3486. [Epub ahead of print]
2. Novello S, Mazières J, Oh IJ, de Castro J, Migliorino MR, Helland Å, Dziadziuszko R, **Griesinger F.**, Kotb A, Zeaiter A, Cardona A, Balas B, Johannsdottir HK, Das-Gupta A, Wolf J. Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study. *Ann Oncol.* 2018 Jun 1;29(6):1409-1416. doi: 10.1093/annonc/mdy121
3. Plenker D, Bertrand M, de Langen AJ, Riedel R, Lorenz C, Scheel AH, Müller J, Brägelmann J, Daßler-Plenker J, Kobe C, Persigehl T, Kluge A, Wurdinger T, Schellen P, Hartmann G, Zacherle T, Menon R, Thunnissen E, Büttner R, **Griesinger F.**, Wolf J, Heukamp L, Sos ML, Heuckmann JM. Structural Alterations of MET Trigger Response to MET Kinase Inhibition in Lung Adenocarcinoma Patients. *Clin Cancer Res.* 2018 Mar 15;24(6):1337-1343. doi: 10.1158/1078-0432.CCR-17-3001. Epub 2017 Dec 28.
4. **Griesinger F.** [Current Aspects of Diagnosis and Treatment of Lung Cancer]. *Dtsch Med Wochenschr.* 2017 Dec;142(24):1808-1812. doi: 10.1055/s-0043-112779. Epub 2017 Dec 5. German.
5. Martin M, Holmes FA, Ejlersen B, Delaloge S, Moy B, Iwata H, von Minckwitz G, Chia SKL, Mansi J, Barrios CH, Gnant M, Tomašević Z, Denduluri N, Šeparović R, Gokmen E, Bashford A, Ruiz Borrego M, Kim SB, Jakobsen EH, Cicenienė A, Inoue K, Overkamp F, Heijns JB, Armstrong AC, Link JS, Joy AA, Bryce R, Wong A, Moran S, Yao B, Xu F, Auerbach A, Buyse M, Chan A; ExteNET Study Group. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol.* 2017 Dec;18(12):1688-1700. doi: 10.1016/S1470-2045(17)30717-9. Epub 2017
6. Lakis S, Heukamp LC, **Griesinger F.** Detection of Discrepant Driver Mutations in a Patient with Two Synchronous Primary Non-Small Cell Lung Cancers (NSCLCs) with Liquid Biopsy. *J Thorac Oncol.* 2017 Nov;12(11):e186-e188. doi: 10.1016/j.jtho.2017.07.018.
7. Concordance between comprehensive cancer genome profiling in plasma and tumor specimens. Judith N Müller¹, Markus Falk^{2,3}, Jatin Talwar¹, Nicole Neemann¹, Erika Mariotti¹, Miriam Bertrand¹, Sotirios Lakis¹, Roopika Menon¹, Christian Gloeckner¹, Markus Tiemann^{2,3}, Lukas C Heukamp^{1,2,3}, Roman K Thomas⁴, **Frank Griesinger** ^{3,4} & Johannes M Heuckmann¹ *J Thoracic Oncol.* 2017, accepted for publication
8. Detection of discrepant driver mutations in a patient with two synchronous primary non-small cell lung cancers (NSCLC) with liquid biopsy Sotirios Lakis ^{1,2,3}, Lukas C Heukamp ^{1,2,3}, **Frank Griesinger** ^{1,4} *J Thoracic Oncol.* 2017, accepted for publication
9. Herrlinger U, Schäfer N, Fimmers R, **Griesinger F.**, Rauch M, Kirchen H, Roth P, Glas M, Bamberg M, Martus P, Thiel E, Korfel A, Weller M. Early whole brain radiotherapy in primary CNS lymphoma: negative impact on quality of life in the randomized G-PCNSL-SG1 trial. *J Cancer Res Clin Oncol.* 2017 Apr 22. doi: 10.1007/s00432-017-2423-5. [Epub ahead of print]
10. von Laffert M, Schirmacher P, Warth A, Weichert W, Büttner R, Huber RM, Wolf J, **Griesinger F.**, Dietel M, Grohé C. ALK-Testing in non-small cell lung cancer (NSCLC): Immunohistochemistry (IHC) and/or fluorescence in-situ Hybridisation (FISH)? Statement of the Germany Society for Pathology (DGP) and the Working

Group Thoracic Oncology (AIO) of the German Cancer Society e.V. (Stellungnahme der Deutschen Gesellschaft für Pathologie und der AG Thorakale Onkologie der Arbeitsgemeinschaft Onkologie/Deutsche Krebsgesellschaft e.V.). Lung Cancer. 2017 Jan;103:1-5. doi: 10.1016/j.lungcan.2016.11.008.

11. Mok TS, Wu Y-L, Ahn M-J, Garassino MC, Kim HR, Ramalingam SS, Shepherd FA, He Y, Akamatsu H, Theelen WS, Lee CK, Sebastian M, Templeton A, Mann H, Marotti M, Ghiorghiu S, Papadimitrakopoulou VA; AURA3 Investigators. Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. *N Engl J Med*. 2017 Feb 16;376(7):629-640. doi: 10.1056/NEJMoa1612674.
12. Schuette W, Dietel M, Thomas M, Eberhardt W, Griesinger F, Zirrgiebel U, Radke S, Schirmacher P.[Exon-dependent Subgroup-analysis of the Non-interventional REASON-Study: PFS and OS in EGFR-mutated NSCLC Patients Treated with Gefitinib or Chemotherapy]. *Pneumologie*. 2016 Aug;70(8):514-21. doi: 10.1055/s-0042-109749. Epub 2016 Aug 11. German.
13. Heukamp L, Menon R, Müller J, Lakis S, Netchaeva M, Griesinger F, Eberhardt W, Heuckmann JM. 65P NEOLiquid: Detection of KIF5B-RET fusions in liquid biopsy samples.*J Thorac Oncol*. 2016 Apr;11(4 Suppl):S82-3. doi: 10.1016/S1556-0864(16)30178-2. Epub 2016 Apr 15. No abstract available.
14. Menon R, Müller J, Schneider P, Lakis S, Thress K, Wolf J, Heukamp L, Heuckmann JM, **Griesinger F**. A Novel EGFR C797 Variant Detected in a Pleural Biopsy Specimen from an Osimertinib-Treated Patient Using a Comprehensive Hybrid Capture-Based Next-Generation Sequencing Assay.*J Thorac Oncol*. 2016 Apr 13. pii: S1556-0864(16)30090-9. doi: 10.1016/j.jtho.2016.04.005. [Epub ahead of print] No abstract available.
15. de Marinis F, Bria E, Ciardiello F, Crinò L, Douillard JY, Griesinger F, Lambrechts D, Perol M, Ramalingam SS, Smit EF, Gridelli C. International Experts Panel Meeting of the Italian Association of Thoracic Oncology on Antiangiogenic Drugs for Non-Small Cell Lung Cancer: Realities and Hopes.*J Thorac Oncol*. 2016 Jul;11(7):1153-69. doi: 10.1016/j.jtho.2016.03.015. Epub 2016 Apr 5.
16. von Laffert M, Schirmacher P, Warth A, Weichert W, Büttner R, Huber RM, Wolf J, **Griesinger F.**, Dietel M, Grohé C. [Statement of the German Society for Pathology and the working group thoracic oncology of the working group oncology/German Cancer Society on ALK testing in NSCLC : Immunohistochemistry and/or FISH?].*Pathologe*. 2016 Mar;37(2):187-92. doi: 10.1007/s00292-016-0152-1. German. No abstract available.
17. von Laffert M, Schirmacher P, Warth A, Weichert W, Büttner R, Huber RM, Wolf J, **Griesinger F.**, Dietel M, Grohé Ch. [ALK-Diagnostics in NSCLC - Immunohistochemistry (IHC) and/or Fluorescence-in-situ Hybridisation (FISH)]. *Pneumologie*. 2016 Apr;70(4):277-81. doi: 10.1055/s-0042-102626. Epub 2016 Mar 16. German.
18. Kreuter M, Vansteenkiste J, Fischer JR, Eberhardt WE, Zabeck H, Kollmeier J, Serke M, Frickhofen N, Reck M, Engel-Riedel W, Neumann S, Thomeer M, Schumann C, De Leyn P, Graeter T, Stamatidis G, **Griesinger F.**, Thomas M; TREAT investigators. Three-Year Follow-Up of a Randomized Phase II Trial on Refinement of Early-Stage NSCLC Adjuvant Chemotherapy with Cisplatin and Pemetrexed versus Cisplatin and Vinorelbine (the TREAT Study). *J Thorac Oncol*. 2016 Jan;11(1):85-93. doi: 10.1016/j.jtho.2015.09.014.
19. Heigener DF, Schumann C, Sebastian M, Sadjadian P, Stehle I, Märten A, Lüers A, **Griesinger F.**, Scheffler M; Afatinib Compassionate Use Consortium (ACUC). Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors. *Oncologist*. 2015 Oct;20(10):1167-74. doi: 10.1634/theoncologist.2015-0073. Epub 2015 Sep 9.
20. Rödel C, Graeven U, Fietkau R, Hohenberger W, Hothorn T, Arnold D, Hofheinz RD, Ghadimi M, Wolff HA, Lang-Welzenbach M, Raab HR, Wittekind C, Ströbel P, Staib L, Wilhelm M, Grabenbauer GG, Hoffmanns H, Lindemann F, Schlenska-Lange A, Folprecht G, Sauer R, Liersch T; German Rectal Cancer Study Group. Oxaliplatin

added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. *Lancet Oncol.* 2015 Aug;16(8):979-89. doi: 10.1016/S1470-2045(15)00159-X. Epub 2015 Jul 15.

21. Korfel A, Thiel E, Martus P, Möhle R, **Griesinger F.**, Rauch M, Röth A, Hertenstein B, Fischer T, Hundsberger T, Mergenthaler HG, Junghanß C, Birnbaum T, Fischer L, Jahnke K, Herrlinger U, Roth P, Bamberg M, Pietsch T, Weller M. Randomized phase III study of whole-brain radiotherapy for primary CNS lymphoma. *Neurology.* 2015 Mar 24;84(12):1242-8. doi: 10.1212/WNL.0000000000001395. Epub 2015 Feb 25.
22. Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Špička I, Oriol A, Hájek R, Rosiñol L, Siegel DS, Mihaylov GG, Goranova-Marinova V, Rajnics P, Suvorov A, Niesvizky R, Jakubowiak AJ, San-Miguel JF, Ludwig H, Wang M, Maisnar V, Minarik J, Bensinger WI, Mateos MV, Ben-Yehuda D, Kukreti V, Zojwalla N, Tonda ME, Yang X, Xing B, Moreau P, Palumbo A; ASPIRE Investigators. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. *N Engl J Med.* 2015 Jan 8;372(2):142-52. doi: 10.1056/NEJMoa1411321. Epub 2014 Dec 6.
23. Sebastian M, Niederle N, Thomas M, Reck M, Schmittel A, Fischer B, Overbeck T, Gröschel A, Deppermann M, Pirker R, Huber RM, Eberhardt W, **Griesinger F.** [Molecular genetic tests in advanced non-small cell lung cancer: practical relevance]. *Dtsch Med Wochenschr.* 2014 Oct;139(41):2096-100. doi: 10.1055/s-0034-1387294. Epub 2014 Sep 30. Review. German. No abstract available.
24. Hoffknecht P, Tufman A, Wehler T, Pelzer T, Wiewrodt R, Schütz M, Serke M, Stöhlmacher-Williams J, Märten A, Maria Huber R, Dickgreber NJ; Afatinib Compassionate Use Consortium (ACUC). Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease. *J Thorac Oncol.* 2015 Jan;10(1):156-63. doi: 10.1097/JTO.0000000000000380.
25. Schuler M, Fischer JR, Grohé C, Gütz S, Thomas M, Kimmich M, Schneider CP, Laack E, Märten A; Afatinib Compassionate Use Consortium. Experience with afatinib in patients with non-small cell lung cancer progressing after clinical benefit from gefitinib and erlotinib. *Oncologist.* 2014 Oct;19(10):1100-9. doi: 10.1634/theoncologist.2014-0103. Epub 2014 Sep 17.
26. Kreher S, Strehlow F, Martus P, Roth P, Hertenstein B, Röth A, Birnbaum T, **Griesinger F.**, Rauch M, Kanz L, Thiel E, Weller M, Korfel A. Prognostic impact of intraocular involvement in primary CNS lymphoma: experience from the G-PCNSL-SG1 trial. *Ann Hematol.* 2015 Mar; 94(3):409-14. doi: 10.1007/s00277-014-2212-z. Epub 2014 Sep 13.
27. Hohloch K, Bertram N, Trümper L, Beissbarth T, **Griesinger F.** Superior vena cava syndrome caused by a malignant tumor: a retrospective single-center analysis of 124 cases. *J Cancer Res Clin Oncol.* 2014 Dec;140(12):2129-34. doi: 10.1007/s00432-014-1764-6. Epub 2014 Jul
28. Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Špička I, Oriol A, Hájek R, Rosiñol L, Siegel DS, Mihaylov GG, Goranova-Marinova V, Rajnics P, Suvorov A, Niesvizky R, Jakubowiak AJ, San-Miguel JF, Ludwig H, Wang M, Maisnar V, Minarik J, Bensinger WI, Mateos MV, Ben-Yehuda D, Kukreti V, Zojwalla N, Tonda ME, Yang X, Xing B, Moreau P, Palumbo A; ASPIRE Investigators. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. *N Engl J Med.* 2015 Jan 8;372(2):142-52. doi: 10.1056/NEJMoa1411321. Epub 2014 Dec 6.
29. Kreuter M, Vansteenkiste J, Herth FJ, Fischer JR, Eberhardt W, Zuna I, Reinmuth N, **Griesinger F.**, Thomas M; TREAT investigators. Impact and safety of adjuvant chemotherapy on pulmonary function in early stage non-small cell lung cancer. *Respiration.* 2014;87(3):204-10. doi: 10.1159/000355361. Epub 2013 Oct 30. Impact Faktor/Wichtungsfaktor per Kategorie: 2,924/2,570

30. (Butts C, Socinski MA, Mitchell PL, Thatcher N, Havel L, Krzakowski M, Nawrocki S, Ciuleanu TE, Bosquée L, Trigo JM, Spira A, Tremblay L, Nyman J, Ramlau R, Wickart-Johansson G, Ellis P, Gladkov O, Pereira JR, Eberhardt WE, Helwig C, Schröder A, Shepherd FA; START trial team. Tecemotide (L-PLP25) versus placebo after chemoradiotherapy for stage III non small cell lung cancer (START): a randomized, double-blind phase 3 trial. *Lancet Oncol.* 2014 Jan;15(1):59-68. doi: 10.1016/S1470-2045(13)70510-2. Epub 2013 Dec 9. Impact Faktor/Wichtungsfaktor per Kategorie: 24,725/2,713)
31. **Griesinger F.**, Halbfass V, Conradi I et al. Acquired resistance in NSCLC with EGFR mutation treated with TKI's: single center experience and treatment outcome. *Onkologie*:2013;36:30-31. Impact Faktor/Wichtungsfaktor per Kategorie: 0,835/2,713
32. Halbfass V, Prenzel R, Scriba D et al. Incidence of EGFR , KRAS, BAF, ALK and p53 alterations in a cohort of 159 consecutively tested patients from 1 DKG certified lung cancer center and correlation with clinical characteristics. *Onkologie* 2013; 36;251. Impact Faktor/Wichtungsfaktor per Kategorie: 0,835/2,713
33. **Griesinger F.**, Prenzel R, Hoheisel M et al. Second line chemotherapy exposure in a DKG certified lung cancer center: Experience of 3 years. *Onkologie* 2013;36:252-253. Impact Faktor/Wichtungsfaktor per Kategorie: 0,835/2,713
34. **Griesinger F.**, Falk M, Conradi I et al. Pathologic complete remission after induction chemotherapy and intercalated erlotinib in EGFR mutated adenocarcinoma stage IIIA: case report:*Onkologie* 2013;36;252-253. Impact Faktor/Wichtungsfaktor per Kategorie: 0,835/2,713
35. **Griesinger F.**, Falk M, Henke RP et al., ROS1 rearrangement in a adenosquamous NSCLC and near CR with Crizotinib: a case report: *Onkologie* 2013;36:253 Impact Faktor/Wichtungsfaktor per Kategorie: 0,835/2,713
36. **Griesinger F.**, Conradi I, Halbfass V et al. ALK rearrangement in combination with a kras mutation in a smoker with adenocarcinoma of the lung: first case report: *Onkologie* 2013;36;254. Impact Faktor/Wichtungsfaktor per Kategorie: 0,835/2,713
37. **Griesinger F.**, Falk M, Hallas C et al. Primary EGFR T790M mutation leads to primary TKI resistance and erlotinib therapeutic failure: a case report. *Onkologie* 2013; 36:254. Impact Faktor/Wichtungsfaktor per Kategorie: 0,835/2,713
38. **Griesinger F.**, Huber RM, Thomas M, Wolf M. Structures and ways of decision making in thoracic oncology: forword. *Onkologie.* 2013;36 Suppl 6:1. German. No abstract available. Impact Faktor/Wichtungsfaktor per Kategorie: 0,835/2,713
39. Overbeck T, Schäper C, **Griesinger F.**, Gröschel A, Haug A, Leschber G, Pfluger T, Pöttgen C. Tumor Conference I. *Onkologie.* 2013;36 Suppl 6:2-4. doi: 10.1159/000353714. Epub 2013 Aug 12. German. No abstract available. Impact Faktor/Wichtungsfaktor per Kategorie: 0,835/2,713
40. Tabriz N, Tannapfel A, **Griesinger F.**, Weyhe D. Chloroma of pancreas-initial manifestation of a secondary leukemia after stem cell transplantation case report and review of the literature. *J Gastrointest Surg.* 2013 Jul;17(7):1331-5. doi: 10.1007/s11605-013-2166-9. Epub 2013 Feb 16. Impact Faktor/Wichtungsfaktor per Kategorie: 2,391/2,403
41. Kreuter M, Vansteenkiste J, Fischer JR, Eberhardt W, Zabeck H, Kollmeier J, Serke M, Frickhofen N, Reck M, Engel-Riedel W, Neumann S, Thomeer M, Schumann C, De Leyn P, Graeter T, Stamatis G, Zuna I, **Griesinger F.**, Thomas M; TREAT investigators. Randomized phase 2 trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed versus cisplatin and vinorelbine: the TREAT study. *Ann Oncol.* 2013 Apr;24(4):986-92. doi: 10.1093/annonc/mds578. Epub 2012 Nov 15. Impact Faktor/Wichtungsfaktor per Kategorie: 6,578/2,713
42. Thatcher N, Lopez PG, Paclakis N et al. Cumulative exposure (EXP) to bevacizumab (BV) maintenance after induction therapy and survival in advanced non-small cell lung cancer (NSCLC). A time-dependent analysis from the SAIO (MO19390) study. *Annals of Oncology* 2012; 23;419-420 Impact Faktor/Wichtungsfaktor per Kategorie:6,578/2,713

43. (Rödel C, Liersch T, Becker H, Fietkau R, Hohenberger W, Hothorn T, Graeven U, Arnold D, Lang-Welzenbach M, Raab HR, Sülberg H, Wittekind C, Potapov S, Staib L, Hess C, Weigang-Köhler K, Grabenbauer GG, Hoffmanns H, Lindemann F, Schlenska-Lange A, Folprecht G, Sauer R); German Rectal Cancer Study Group. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. *Lancet Oncol.* 2012 Jul;13(7):679-87. doi: 10.1016/S1470-2045(12)70187-0. Epub 2012 May 23. . Impact Faktor/Wichtungsfaktor per Kategorie:24,725/2,713
44. Nitsche M, Christiansen H, Lederer K, **Griesinger F.**, Schmidberger H, Pradier O. Fludarabine combined with radiotherapy in patients with locally advanced NSCLC lung carcinoma: a phase I study. *J Cancer Res Clin Oncol.* 2012 Jul;138(7):1113-20. doi: 10.1007/s00432-012-1185-3. Epub 2012 Mar 10 Impact Faktor/Wichtungsfaktor per Kategorie:3,009/2,713
45. (Dufour A, Schneider F, Hoster E, Benthous T, Ksienzyk B, Schneider S, Kakadia PM, Sauerland MC, Berdel WE, Büchner T, Wörmann B, Braess J, Subklewe M, Hiddemann W, Bohlander SK, Spiekermann K; AML CG study group). Monoallelic CEBPA mutations in normal karyotype acute myeloid leukemia: independent favorable prognostic factor within NPM1 mutated patients. *Ann Hematol.* 2012 Jul;91(7):1051-63. doi: 10.1007/s00277-012-1423-4. Epub 2012 Feb 24. Impact Faktor/Wichtungsfaktor per Kategorie: 2,396/2,445
46. Dansin E, Cinieri S, Garrido P, Griesinger F, Isla D, Koehler M, Kohlhaeufel M. MO19390 (SAiL): bleeding events in a phase IV study of first-line bevacizumab with chemotherapy in patients with advanced non-squamous NSCLC. *Lung Cancer.* 2012 Jun;76(3):373-9. doi: 10.1016/j.lungcan.2011.11.020. Epub 2012 Jan 10. . Impact Faktor/Wichtungsfaktor per Kategorie: 3,737/2,570
47. **Griesinger F.**, Huber RM, Thomas M, Wolf M. [Thoracic oncology - optimization through integrated approaches, quality assurance, and molecular biology. Forward]. *Onkologie.* 2012;35 Suppl 3:1. doi: 10.1159/000338991. Epub 2012 May 15. German. No abstract available. Impact Faktor/Wichtungsfaktor per Kategorie: 0,835/2,713
48. Eberhardt W, **Griesinger F.**, Filipits M, Winter H. [Early staging in non-small cell lung cancer]. *Onkologie.* 2012;35 Suppl 3:6-9. doi: 10.1159/000338977. Epub 2012 May 15. German. No abstract available. Impact Faktor/Wichtungsfaktor per Kategorie: 0,835/2,713
49. Gridelli C, Bennouna J, de Castro J, Dingemans AM, **Griesinger F.**, Grossi F, Rossi A, Thatcher N, Wong EK, Langer C. Randomized Phase IIIb Trial Evaluating the Continuation of Bevacizumab Beyond Disease Progression in Patients with Advanced Non-Squamous Non-Small-Cell Lung Cancer after First-Line Treatment with Bevacizumab Plus Platinum-Based Chemotherapy: Treatment Rationale and Protocol Dynamics of the AvaALL (MO22097) Trial. *Clin Lung Cancer.* 2011 Jun 24. [Epub ahead of print] Impact Faktor/Wichtungsfaktor per Kategorie: 17,879/2,713
50. Fischer JR, **Griesinger F.**, Fink T, Salm T, Marseille A, Wolf M. Docetaxel-carboplatin chemotherapy combined with cetuximab in patients with locally advanced or metastatic non small-cell lung cancer (NSCLC)-Results of the nonrandomised phase II study TaxErb. *Lung Cancer.* 2011 Sep 9. [Epub ahead of print] Impact Faktor/Wichtungsfaktor per Kategorie: 3,737/2,570
51. Overbeck TR, Griesinger F. Two cases of psoriasis responding to erlotinib: time to revisiting inhibition of epidermal growth factor receptor in psoriasis therapy?. *Dermatology.* 2012;225(2):179-82. doi: 10.1159/000342786. Epub 2012 Oct 20. Review. Impact Faktor/Wichtungsfaktor per Kategorie: 1,685/1,536
52. T. Rippberger, M. Tauscher, D. Haase, **F. Griesinger**, B. Schlegelberger, and D. Steinemann Managing individuals with propensity to myeloid malignancies due to germline RUNX1 deficiency.. 2011, *Haematologica* Aug 31, epub Impact Faktor/Wichtungsfaktor per Kategorie: 5,868/2,445
53. Gridelli C, Bennouna J, de Castro J et al. Randomized Phase IIIb trial evaluation the continuation of bevacizumab beyond disease progression in patients with advanced

- non –squamous non-small cell lung cancer after first line treatment with bevacizumab plus platinum base chemotherapy: treatment rationale and protocol dynamics of the Ava ALL (MO22097) trial: *Clinical lung Cancer* 2011;12:407-411. Impact Faktor/Wichtungsfaktor per Kategorie: 3,220/2,713
54. Hohloch K, Lakhani VJ, Sahlmann C, Wulf G, Meller J, Trümper L, **Griesinger F.** Tandem-high dose therapy in relapsed and refractory B-cell lymphoma, Phase II trial of a myeloablative chemotherapy followed by escalated radioimmunotherapy with I131 anti CD20 antibody. *Ann. Hematol* 2011 Nov;90(11):1307-15. doi: 10.1007/s00277-011-1199-y. Epub 2011 Mar 1. in press Impact Faktor/Wichtungsfaktor per Kategorie: 2,396/2,445
 55. Jahnke K, Martus P, Lokka S et al., Prognostic factors and score for response and survival in primary central nervous system lymphoma from a randomized phase III trial. *Onkologie* 2011;34:296. Impact Faktor/Wichtungsfaktor per Kategorie: 0,835/2,713
 56. Meyer F, **Griesinger F.**, Willborn K, Sambale R, Thomé C. Treatment strategies for the multidisciplinary management of spinal metastasis. *Dtsch Med Wochenschr.* 2011 Sep;136(38):1907-12. Epub 2011 Sep 13. German. Impact Faktor/Wichtungsfaktor per Kategorie: 0,550x2=1,10/1,328
 57. Goeckenjan G, Sitter H, Thomas M, Branscheid D, Flentje M, Griesinger F, Niederle N, Stuschke M, Blum T, Deppermann KM, Ficker JH, Freitag L, Lübke AS, Reinhold T, Späth-Schwalbe E, Ukena D, Wickert M, Wolf M, Andreas S, Auberger T, Baum RP, Baysal B, Beuth J, Bickeböller H, Böcking A, Bohle RM, Brüske I, Burghuber O, Dickgreber N, Diederich S, Dienemann H, Eberhardt W, Eggeling S, Fink T, Fischer B, Franke M, Friedel G, Gauler T, Gütz S, Hautmann H, Hellmann A, Hellwig D, Herth F, Heußel CP, Hilbe W, Hoffmeyer F, Horneber M, Huber RM, Hübner J, Kauczor HU, Kirchbacher K, Kirsten D, Kraus T, Lang SM, Martens U, Mohn-Staudner A, Müller KM, Müller-Nordhorn J, Nowak D, Ochmann U, Passlick B, Petersen I, Pirker R, Pokrajac B, Reck M, Riha S, Rube C, Schmittel A, Schönfeld N, Schütte W, Serke M, Stamatis G, Steingraber M, Steins M, Stoelben E, Swoboda L, Teschler H, Tessen HW, Weber M, Werner A, Wichmann HE, Irlinger Wimmer E, Witt C, Worth H. Prevention, Diagnosis, Therapy, and Follow-up of Lung Cancer. *Pneumologie.* 2011 Aug;65(8):e51-e75. Epub 2011 Aug 9. German. No abstract available. Impact Faktor/Wichtungsfaktor per Kategorie: 0,2/entfällt
 58. **Griesinger F.**, Huber RM, Thomas M. *Onkologie.* 2011;34 Suppl 4:1. Epub 2011 May 13. German. No abstract available. Impact Faktor/Wichtungsfaktor per Kategorie: 0,835/2,713
 59. A Stenger I, Tomala C, Pietsch M, Olgemoeller U, Koerber W, Fischer B, Sebastian M, Truemper L, Overbeck T, Griesinger F. Mitomycin C in combination with vinorelbine or cisplatin and erythropoietin in pretreated patients with in field relapse after radiation therapy of non-small cell lung cancer: a phase II trial of the AIO. *MEMO* 2011 Impact Factor 0,2
 60. Halbfass V, Falk M, Prenzel R et al. Incidence of molecular targets (EGFR mutation, EML4-ALK, BRAF, and kras) in metastatic NSCLC in a certified lung cancer Hospital. *J Thor Oncol.* 2011;6:S1082-1083. Impact Faktor/Wichtungsfaktor per Kategorie: 5,800/2,570
 61. Jahnke K, Korfel AI, Martus P et al. Prognostic factors for response and survival in primary central nervous system lymphoma (PCNSL) from a randomized phase III trial (G-PCNSL-SG-1) *J Clin Oncol* 2011;29:S2004 Impact Faktor/Wichtungsfaktor per Kategorie: 17,879/2,713
 62. Kreuter M, Vansteenkiste JF, Fischer JR et al. Randomized phase II trial on refinement of early stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed (CPx) versus cisplatin and vinorelbine (CVb): TREAT. *J Clin Oncol* 2011;29; S002. Impact Faktor/Wichtungsfaktor per Kategorie: 17,879/2,713
 63. Ripperger T, Steinemann D, Tauscher M et al. Non-syndromic thrombocytopenia with propensity to myeloid malignancies due to a de novo microdeletion on chromosome

- 21q involving RUNX1: what to do next. *Ann Hematology* 2011;90:S5-6: Impact Faktor/Wichtungsfaktor per Kategorie: 2,396/2,445
64. Goeckenjan G, Sitter H, Thomas M, Branscheid D, Flentje M, Griesinger F, Niederle N, Stuschke M, Blum T, Deppermann KM, Ficker JH, Freitag L, Lübke AS, Reinhold T, Späth-Schwalbe E, Ukena D, Wickert M, Wolf M, Andreas S, Auberger T, Baum RP, Baysal B, Beuth J, Bickeböller H, Böcking A, Bohle RM, Brüske I, Burghuber O, Dickgreber N, Diederich S, Dienemann H, Eberhardt W, Eggeling S, Fink T, Fischer B, Franke M, Friedel G, Gauler T, Gütz S, Hautmann H, Hellmann A, Hellwig D, Herth F, Heußel CP, Hilbe W, Hoffmeyer F, Horneber M, Huber RM, Hübner J, Kauczor HU, Kirchbacher K, Kirsten D, Kraus T, Lang SM, Martens U, Mohn-Staudner A, Müller KM, Müller-Nordhorn J, Nowak D, Ochmann U, Passlick B, Petersen I, Pirker R, Pokrajac B, Reck M, Riha S, Rübe C, Schmittel A, Schönfeld N, Schütte W, Serke M, Stamatis G, Steingraber M, Steins M, Stoelben E, Swoboda L, Teschler H, Tessen HW, Weber M, Werner A, Wichmann HE, Irlinger Wimmer E, Witt C, Worth H. Prevention, Diagnosis, Therapy, and Follow-up of Lung Cancer. *Pneumologie*. 2011 65(8):39-59. German. No abstract available. Impact Faktor/Wichtungsfaktor per Kategorie: 0,2/entfällt
 65. (Krug U, Röllig C, Koschmieder A, Heinecke A, Sauerland MC, Schaich M, Thiede C, Kramer M, Braess J, Spiekermann K, Haferlach T, Haferlach C, Koschmieder S, Rohde C, Serve H, Wörmann B, Hiddemann W, Ehninger G, Berdel WE, Büchner T, Müller-Tidow C; German Acute Myeloid Leukaemia Cooperative Group; Study Alliance Leukemia Investigators. Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes. *Lancet*. 2010 Dec 11;376(9757):2000-8. Epub 2010 Dec 3.) Impact Faktor/Wichtungsfaktor per Kategorie: 39,207/1,328
 66. Thiel E, Korfel A, Martus P, Kanz L, **Griesinger F.**, Rauch M, Röth A, Hertenstein B, von Toll T, Hundsberger T, Mergenthaler HG, Leithäuser M, Birnbaum T, Fischer L, Jahnke K, Herrlinger U, Plasswilm L, Nägele T, Pietsch T, Bamberg M, Weller M. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. *Lancet Oncol*. 2010 Nov;11(11):1036-47. Epub 2010 Oct 20. Impact Faktor/Wichtungsfaktor per Kategorie: 24,725/2,713
 67. Crino L, Franke F, Sadjadian P, Jaeger E, **Griesinger F.** Final safety outcomes by chemotherapy (CT) regimen for the MO19390 (SAIL) trial: First line bevacizumab (BV) based therapy in advanced non-small cell lung cancer (NSCLC). *Ann Oncol* 2010;21;143. Impact Faktor/Wichtungsfaktor per Kategorie: 6,578/2,713
 68. **Griesinger F.**, Bearz A, Eberhardt W et al. Safety of first line bevacizumab based therapy in the SAIL (MO19390) Trial: Central tumor location (CTL) and hypertension (HTN) in patients (pts) with advanced non-small cell lung cancer (NSCLC). *Ann Oncol* 2010;21:144. Impact Faktor/Wichtungsfaktor per Kategorie: 0,835/2,713
 69. Korfel A, Weller M, Martus P et al. The role of whole brain radiotherapy in primary management of patients with primary central nervous system lymphoma (G-PCNSL-SG1 trial) *onkologie* 2010;33;99. Impact Faktor/Wichtungsfaktor per Kategorie: 0,835/2,713
 70. Crinò L, Dansin E, Garrido P, **Griesinger F.**, Laskin J, Pavlakis N, Stroiakovski D, Thatcher N, Tsai CM, Wu YL, Zhou C. Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAIL, MO19390): a phase 4 study. *Lancet Oncol*. 2010 Aug;11(8):733-40. Epub 2010 Jul 23 Impact Faktor/Wichtungsfaktor per Kategorie: 24,725/2,713
 71. Gatzemeier U, **Griesinger F.**, Huber RM, Thomas M. A Paradigm Shift in Local and Systemic treatment of NSCLC ? *Onkologie* 2010;33;1. Impact Faktor/Wichtungsfaktor per Kategorie: 0,835/2,713
 72. Fischer JR, **Griesinger F.**, Fink T et al. Docetaxel-carboplatin chemotherapy combined with cetuximab in patients with locally advanced or metastasized non-small

- cell lung cancer (NSCLC): results of the nonrandomized phase II study TaxErb. J Clin Oncol 2010;28:S7546. Impact Faktor/Wichtungsfaktor per Kategorie: 17,879/2,713
73. Thiel E, Korfel A, Martus P et al. Should whole brain radiotherapy be considered standard of care in newly diagnosed primary central nervous system lymphoma? The G-PCNLS SG1 randomized phase IV trial. J Clin Oncol 2010;28:S8008. Impact Faktor/Wichtungsfaktor per Kategorie: 17,879/2,713
 74. Goeckenjan G, Sitter H, Thomas M, Branscheid D, Flentje M, Griesinger F, Niederle N, Stuschke M, Blum T, Deppermann KM, Ficker JH, Freitag L, Lübke AS, Reinhold T, Späth-Schwalbe E, Ukena D, Wickert M, Wolf M, Andreas S, Auberger T, Baum RP, Baysal B, Beuth J, Bickeböller H, Böcking A, Bohle RM, Brüske I, Burghuber O, Dickgreber N, Diederich S, Dienemann H, Eberhardt W, Eggeling S, Fink T, Fischer B, Franke M, Friedel G, Gauler T, Gütz S, Hautmann H, Hellmann A, Hellwig D, Herth F, Heußel CP, Hilbe W, Hoffmeyer F, Horneber M, Huber RM, Hübner J, Kauczor HU, Kirchbacher K, Kirsten D, Kraus T, Lang SM, Martens U, Mohn-Staudner A, Müller KM, Müller-Nordhorn J, Nowak D, Ochmann U, Passlick B, Petersen I, Pirker R, Pokrajac B, Reck M, Riha S, Rübe C, Schmittel A, Schönfeld N, Schütte W, Serke M, Stamatis G, Steingraber M, Steins M, Stoelben E, Swoboda L, Teschler H, Tessen HW, Weber M, Werner A, Wichmann HE, Irlinger Wimmer E, Witt C, Worth H. Prevention, Diagnosis, Therapy, and Follow-up of Lung Cancer. Pneumologie. 2010;64 Suppl 2:31-164. Impact Faktor/Wichtungsfaktor per Kategorie: 0,2/entfällt
 75. Agarwal JR, **Griesinger F.**, Stühmer W, Pardo LA. The potassium channel Ether à go-go is a novel prognostic factor with functional relevance in acute myeloid leukemia. Mol Cancer. 2010 Jan 27;9:18. Impact Faktor/Wichtungsfaktor per Kategorie: 5,397/2,713
 76. (Lengfelder E, Haferlach C, Saussele S et al. High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: long term results of the German SMLCG. Leukemia 2009;12:2248-2258. Impact Faktor/Wichtungsfaktor per Kategorie: 9,379/2,445
 77. Dansin E, Tsai CM, Pavlakis N et al. Safety and efficacy of first line bevacizumab based therapy in advanced non-small cell lung cancer (NSCLC) results of the SAIL study (MO19390). EJC Supplements. 2009;7:556. Impact Faktor/Wichtungsfaktor per Kategorie:0,2/entfällt
 78. Garrido P, Thatcher N, Crino L et al. Safety and efficacy of first line bevacizumab (Bv) plus chemotherapy (CT) in elderly patients (pts) with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC) SAIL (MO19390). EJC Supplements. 2009;7:557 Impact Faktor/Wichtungsfaktor per Kategorie:0,2/entfällt
 79. Tsai C, **Griesinger F.**, Laskin J et al. Low incidence of grade 3 bleeding events and low discontinuation rates associated with first line bevacizumab (Bev) in patients with advanced NSCLC: data from the SAIL (MO19390) trial. EJC Supplements 2009;7:557-558 Impact Faktor/Wichtungsfaktor per Kategorie:0,2/entfällt
 80. **Griesinger F.**, Pavlakis N, Garrido P et al. MO19390 (SAIL): Safety and efficacy of first line bevacizumab plus chemotherapy in elderly patients with advanced or recurrent non squamous non-small cell lung cancer (NSCLC). J Thor Oncology. 2009;4:S359-360. Impact Faktor/Wichtungsfaktor per Kategorie: 5,800/2,570
 81. Laskin J, Crino L, Tsai CM et al., MO19390 SAIL: first line bevacizumab based therapy in advanced non-small cell lung cancer (NSCLC) outcome by chemotherapy regimen. J Thor Oncol 2009;4:S359. Impact Faktor/Wichtungsfaktor per Kategorie: 5,800/2,570
 82. Pirker R, Fischer B, Eberhardt W et al. Gemcitabine / vinorelbine followed by paclitaxel versus cisplatin /gemcitabine/vinorelbine versus cisplatin/paclitaxel in advanced non-small cell lung cancer: final results of the AASLC-AIO-3 Phase III trial. J Thor Oncol 2009;4:S286. Impact Faktor/Wichtungsfaktor per Kategorie: 5,800/2,570
 83. Thatcher N, Tsai CM, Laskin J et al. MO19390 SAIL: hypertension in patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC) receiving first line bevacizumab plus chemotherapy. J Thor Oncol 2009;4:S358-S359. Impact Faktor/Wichtungsfaktor per Kategorie: 5,800/2,570

84. Crino L, Mezger J, Griesinger F et al. MO19390 (SAIL): Safety and efficacy of first line bevacizumab (Bv) based therapy in advanced non small cell lung cancer (NSCLC) J Clin Oncol 2009;27:8043 Impact Faktor/Wichtungsfaktor per Kategorie: 17,897/2,713
85. Fischer JR, **Griesinger F.**, Fint T et al. Docetaxel-carboplatin chemotherapy in combination with cetuximab in patients with locally advanced or metastasized non-small cell lung cancer (NSCLC: interim results of the nonrandomized phase II study TaxErb. J Clin Oncol 2009;27:e19062. Impact Faktor/Wichtungsfaktor per Kategorie: 17,897/2,713
86. Thatcher N, Stroyakovskiy D, Zhou C et al. MO19390 (SAIL) Incidence of hemorrhage with first –line bevacizumab (Bv) based therapy in advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2009;27:e19000. Impact Faktor/Wichtungsfaktor per Kategorie: 17,897/2,713
87. (Pirker R, Pereira JR, Szczesna A et al. Cetuximab plus chemotherapy in patients with advanced non-small cell lung cancer (FLEX): an open-label randomized phase III trial. Lancet 2009;373:1525-1531 Impact Faktor/Wichtungsfaktor per Kategorie: 39,207/1,328)
88. (Schlenk RF, Döhner K, Kneba M, Götze K, Hartmann F, Del Valle F, Kirchen H, Koller E, Fischer JT, Bullinger L, Habdank M, Späth D, Groner S, Krebs B, Kayser S, Corbacioglu A, Anhalt A, Benner A, Fröhling S, Döhner H; German-Austrian AML Study Group (AMLSG Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B. Haematologica. 2009 Jan;94(1):54-60. Epub 2008 Dec 4.) Impact Faktor/Wichtungsfaktor per Kategorie: 5,868/2,445)
89. Gatzemeier U, **Griesinger F.**, Huber R, Thomas M. Preface. Onkologie 2009; 32:1 Impact Faktor/Wichtungsfaktor per Kategorie: 0,835/2,713
90. Gatzemeier U, Griesinger F, Huber RM, Thomas M. Onkologie. 2008;31 Suppl 3:V. German. No abstract available.
91. (Schlenk RF, Döhner K, Krauter J, Fröhling S, Corbacioglu A, Bullinger L, Habdank M, Späth D, Morgan M, Benner A, Schlegelberger B, Heil G, Ganser A, Döhner H; German-Austrian Acute Myeloid Leukemia Study Group. Collaborators: Schlimok G, Arnold R, Pezzutto A, Glasmacher A, Germing U, Heit W, Hoelzer D, Derigs HG, Lübbert M, Pralle H, Runde V, **Griesinger F.**, Fiedler W, Salwender H, Kirchner H, Hensel H, Hartmann F, Fischer JT, Kneba M, Hinke A, Kremers S, Götze K, Waterhouse C, del Valle F, Matzdorf A, Grimminger W, Mergenthaler HG, Kirchen H, Brossart P, Bergmann L, Raghavachar A, Petzer A, Koller E, Noens L. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008 May 1;358(18):1909-18).
92. Baesecke J, Podleschny M, Becker A, Seiffert E, Schwiers I, Schwiers R, Haase D, Glass B, Schmitz N, Trümper L, **Griesinger F.** Therapy-associated genetic aberrations in patients treated for non-Hodgkin lymphoma. Br J Haematol. 2008 Apr;141(1):52-9.
93. Steidl U, Steidl C, Ebralidze A, Chapuy B, Han HJ, Will B, Rosenbauer F, Becker A, Wagner K, Koschmieder S, Kobayashi S, Costa DB, Schulz T, O'Brien KB, Verhaak RG, Delwel R, Haase D, Trümper L, Krauter J, Kohwi-Shigematsu T, Griesinger F, Tenen DG. A distal single nucleotide polymorphism alters long-range regulation of the PU.1 gene in acute myeloid leukemia. J Clin Invest. 2007 Sep;117(9):2611-20.
94. Gralla RJ, **Griesinger F.** Interpreting clinical trials in lung cancer: impact of methodology and endpoints. J Thorac Oncol. 2007 Jun;2 Suppl 2:S51-8. Review.
95. Kreuter M, Vansteenkiste J, Griesinger F, Hoffmann H, Dienemann H, De Leyn P, Thomas M. Trial on refinement of early stage non-small cell lung cancer. Adjuvant chemotherapy with pemetrexed and cisplatin versus vinorelbine and cisplatin: the TREAT protocol. BMC Cancer. 2007 May 8;7:77.
96. Hallermann C, Kaune KM, Tiemann M, Kunze E, **Griesinger F.**, Mitteldorf C, Bertsch HP, Neumann C. High frequency of primary cutaneous lymphomas associated with lymphoproliferative disorders of different lineage. Ann Hematol. 2007 Jul; 86(7):509-

15. Epub 2007 Mar 6. Erratum in: *Ann Hematol.* 2007 Jul;86(7):517. Kaune, Matthias Kjell [corrected to Kaune, Kjell Matthias].
97. Chapuy B, Wulf G, Tessen HW, **Griesinger F.**, Trümper L, Schroers R. [Asymptomatic 32 year old female smoker with persistent polyclonal lymphocytosis] *Internist (Berl)*. 2007 Mar;48(3):314-8. German.
98. Eberhardt W, Fietkau R, **Griesinger F.**, Passlick B, Stuschke M. [Surgery and adjuvant therapy in non-small-cell lung carcinoma (NSCLC). (stage I through operable stage IIIA)] *Onkologie*. 2006 Sep;29 Suppl 2:7-10. Epub 2006 Sep 6. Review. German. No abstract available
99. Gatzemeier U, **Griesinger F.**, Huber RM. [Pillnitz interdisciplinary discussion--summary] *Onkologie*. 2006 Sep;29 Suppl 2:2. Epub 2006 Sep 6. German. No abstract available.
100. Basecke J, Whelan JT, **Griesinger F.**, Bertrand FE. The MLL partial tandem duplication in acute myeloid leukaemia. *Br J Haematol.* 2006 Nov;135(4):438-49. Epub 2006 Sep 11. Review.
101. MRD-AML-BFM Study Group, Langebrake C, Creutzig U, Dworzak M, Hrusak O, Mejstrikova E, **Griesinger F.**, Zimmermann M, Reinhardt D. Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: the MRD-AML-BFM Study Group. *J Clin Oncol.* 2006 Aug 1;24(22):3686-92.
102. Basecke J, Karim K, Podleschny M, Becker A, Glass B, Trumper L, Griesinger F. MLL rearrangements emerge during spontaneous apoptosis of clinical blood samples. *Leukemia.* 2006 Jun;20(6):1193-4. No abstract available.
103. Bäsecke J, Podleschny M, Clemens R, Schnittger S, Viereck V, Trümper L, **Griesinger F.** Lifelong persistence of AML associated MLL partial tandem duplications (MLL-PTD) in healthy adults. *Leuk Res.* 2006 Sep;30(9):1091-6. Epub 2006 Mar 15
104. Meyer C, Schneider B, Jakob S, Strehl S, Attarbaschi A, Schnittger S, Schoch C, Jansen MW, van Dongen JJ, den Boer ML, Pieters R, Ennas MG, Angelucci E, Koehl U, Greil J, **Griesinger F.**, Zur Stadt U, Eckert C, Szczepański T, Niggli FK, Schäfer BW, Kempinski H, Brady HJ, Zuna J, Trka J, Nigro LL, Biondi A, Delabesse E, Macintyre E, Stanulla M, Schrappe M, Haas OA, Burmeister T, Dingermann T, Klingebiel T, Marschalek R. The MLL recombinome of acute leukemias. *Leukemia.* 2006 May;20(5):777-84
105. **Griesinger F.**, Hennig H, Hillmer F, Podleschny M, Steffens R, Pies A, Wormann B, Haase D, Bohlander SK. (2005) A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11.2) translocation in a patient with a clinically typical chronic myeloid leukemia. *Genes Chromosomes Cancer.* 44:329-33.
106. Basecke J, Schwieger M, **Griesinger F.**, Schiedlmeier B, Wulf G, Trumper L, Stocking C. (2005) AML1/ETO promotes the maintenance of early hematopoietic progenitors in NOD/SCID mice but does not abrogate their lineage specific differentiation. *Leuk Lymphoma* 46:265-272.
107. Schroers R, Hildebrandt Y, Steffens R, Becker S, Ohms G, von Bonin F, Haase D, Bertsch HP, Trumper L, **Griesinger F.** (2005). Immunophenotypic and genetic characterization of a CD8 positive mantle cell lymphoma in a patient with concomitant Mycosis fungoides. *Eur J Haematol.* Jul;75(1):78-84.
108. Schroers R, **Griesinger F.**, Trumper L, Haase D, Kulle B, Klein-Hitpass L, Sellmann L, Duhrsen U, Durig J. (2005) Combined analysis of ZAP-70 and CD38 expression as a predictor of disease progression in B-cell chronic lymphocytic leukemia. *Leukemia.*19:750-8.
109. Langebrake C, Brinkmann I, Teigler-Schlegel A, Creutzig U, **Griesinger F.**, Puhmann U, Reinhardt D. (2005) Immunophenotypic differences between diagnosis and relapse in childhood AML: Implications for MRD monitoring. *Cytometry B Clin Cytom.* 63:1-9.
110. Wulf GG, Modlich S, Inagaki N, Reinhardt D, Schroers R, **Griesinger F.**, Trumper L (2004). ABC transporter ABCA3 is expressed in acute myeloid leukemia blast cells and participates in vesicular transport. *Haematologica.* 89:1395-1397.

111. Hallermann C, Middel P, **Griesinger F.**, Gunawan B, Bertsch HP, Neumann C (2004). CD4+ CD56+ blastic tumor of the skin: cytogenetic observations and further evidence of an origin from plasmacytoid dendritic cells. *Eur J Dermatol* 14:317-322.
112. Hallermann C, Kaune K M, Gesk S, Martin-Subero J I, Gunawan B, **Griesinger F.**, Vermeer MH, Santucci M, Pimpinelli N, Willemze R, Siebert R, Neumann C (2004). Molecular cytogenetic analysis of chromosomal breakpoints in the IGH, MYC, BCL6, and MALT1 gene loci in primary cutaneous B-cell lymphomas. *J Invest Dermatol* 123:213-219.
113. Schroers R, Pukrop T, Durig J, Haase, D., Duhrsen, U., Trumper, L., **Griesinger, F.** (2004) B-cell chronic lymphocytic leukemia with aberrant CD8 expression: genetic and immunophenotypic analysis of prognostic factors. *Leuk Lymphoma* 45:1677-1681.
114. **Griesinger F.**, Metz M, Trumper L, Schulz T, Haase D (2004). Secondary leukaemia after cure for locally advanced NSCLC: alkylating type secondary leukaemia after induction therapy with docetaxel and carboplatin for NSCLC IIIB. *Lung Cancer* 44:261-265.
115. Schlenk, R. F., Frohling, S., Hartmann, F., Fischer, J. T., Glasmacher, A., del Valle, F., Grimminger, W., Gotze, K., Waterhouse, C., Schoch, R., Pralle, H., Mergenthaler, H. G., Hensel, M., Koller, E., Kirchen, H., Preiss, J., Salwender, H., Biedermann, H. G., Kremers, S., **Griesinger, F.**, Benner, A., Addamo, B., Dohner, K., Haas, R., Dohner, H. (2004) Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia. *Leukemia* 18: 1798-1803.
116. Zwaan CM, Meshinchi S, Radich JP, Veerman AJ, Huismans DR, Munske L, Podleschny M, Hahlen K, Pieters R, Zimmermann M, Reinhardt D, Harbott J, Creutzig U, Kaspers GJ, **Griesinger F.** (2003): FLT3 internal tandem duplication in 234 children with acute myeloid leukemia (AML): prognostic significance and relation to cellular drug resistance. *Blood*. 102:2387-2394
117. Wassmann B, Scheuring U, Thiede C, Pfeifer H, Bornhäuser M, **Griesinger F.**, Hochhaus A, Schleyer E, Gschaidmeier H, Hoelzer D, Ottmann, OG. (2003) Stable molecular remission induced by imatinib mesylate (STI571) in a patient with CML lymphoid blast crisis relapsing after allogeneic stem cell transplantation. *Bone Marrow Transpl* 31:611-614
118. Schmücking M, Baum, RP, **Griesinger F.**, Presselt N, Bonnet R, Przetak C, Niesen A, Leonhardi J, Lopatta EC, Herse B, Wendt TG (2003) Molecular whole-body cancer staging using positron emission tomography: consequences for therapeutic management and metabolic radiation treatment planning. *Recent Results Cancer Res.* 162:195-202
119. **Griesinger F.**, Oberbeck T, Trümper L (2003) Neue Therapieansätze beim Bronchialkarzinom. *Zeitschrift für Allgemeinmedizin*, 79: 90-97
120. Grundker C, Volker, P, **Griesinger F.**, Ramaswamy A, Nagy A, Schally AV, Emons G (2002). Antitumor effects of the cytotoxic luteinizing hormone-releasing hormone analog AN-152 on human endometrial and ovarian cancers xenografted into nude mice. *Am J Obstet Gynecol* 187:528-537.
121. Reinhardt D, Langebrake C, Creutzig U, Vormoor J, Brune C, Thorwesten M, Ingiliz P, Hrusak O, Dworzak M, **Griesinger F.** (2002) Minimal residual disease in acute myeloid leukemia in children - standardization and evaluation of immunophenotyping in the AML-BFM-98 study, *Klin Padiatr* 214:179-187
122. Basecke J, **Griesinger F.**, Trümper L, Brittinger G. (2002) Leukemia- and lymphoma-associated genetic aberrations in healthy individuals. *Ann Hematol* 81:64-75
123. Basecke J, Feuring-Buske M, Brittinger G, Schaefer UW, Hiddemann W, **Griesinger F.** (2002) Transcription of AML1 in hematopoietic subfractions of normal adults. *Ann Hematol* 81:254-257

124. Baesecke J, Cepek L, Mannhalter C, Krauter J, Hildenhausen S, Brittinger G, Truemper L, **Griesinger F.** (2002) Transcription of AML1-ETO in bone marrow and cord blood of individuals without AML. *Blood* 100: 2267-2268
125. **Griesinger F.**, Janke A, Podleschny, M, Bohlander S (2002). Identification of an ETV6-ARG fusion transcript in combination with an ETV6 point mutation in a multipotent ALL cell line. *Br J Hematol/Br J Haematol.* 119:454-458.
126. Behr, TM, Liersch T, Greiner-Bechert L, **Griesinger F.**, Béhé M, Markus PM, Gratz S, Angerstein C, Brittinger G, Becker H, Goldenberg DM, Becker W. (2002) Radioimmunotherapy of small volume disease of metastatic colorectal cancer. *Cancer* 94:1373-1381
127. Fasching K, Panzer S, Haas OA, Borkhardt A, Marschalek R, **Griesinger F.**, Panzer-Grümayer R (2001) The presence of N regions in the clonotypic DJ rearrangements of the Ig heavy chain genes indicate an exquisitely short latency in t(4;11) positive infant acute lymphoblastic leukemia. *Blood* 98:2272-2274
128. Haase D, Schulz T, Binder C, Fonatsch C, Schnittger S, **Griesinger F.**, Westphal G, Bünger J, Schoch C, Wörmann B, Hallier E. (2002) Increased risk for therapy-induced hematologic malignancies in patients with carcinoma of the breast and combined homozygous gene defects of glutathione transferases M1 and T1. *Leuk Res.* 26:249-254.
129. Buchner T, Hiddemann W, Wormann B, Löffler H, Ludwig WD, Schoch C, Haferlach T, Maschmeyer G, Staib P, Aul C, Heyll GA, Gruneisen A, Rasche H, Eimermacher JH, Balleisen L, Pielken HJ, Reis HE, **Griesinger F.**, Reichle A, Sauerland MC, Heinecke A. (2000) Acute myeloid leukemia in adults: is postconsolidation maintenance therapy necessary? German AMLCG. *Int J Hematol;* 72:285-289
130. Schnittger S, Kinkel U, Schoch C, Heinecke A, Haase D, Haferlach T, Büchner T, Wörmann B, Hiddemann W, **Griesinger F.** (2000) MLL tandem duplication in 387 unselected patients with AML identify a prognostically unfavorable subset of karyotypically normal AML. *Leukemia* 2000; 14:796-804
131. **Griesinger F.**, Pirò-Noack M, Falk M, Kaib N, Troff C, Grove D, Büchner T, Ritter J, Hiddemann W, Wörmann B (1999) Leukemia-associated immunophenotypes by 3-color flow cytometry are observed in 90% of childhood and adult acute lymphoblastic leukemia at diagnosis and predict clinical outcome in remission marrow. *Br. J. Hematol.* 105: 241-255
132. Gillert E, Leis T, Repp R, Reichel M, Hösch A, Breitenlohner I, Angermüller S, Borkhardt A, Harbott J, Lampert F, **Griesinger F.**, Greil J, Fey, G, Marschalek R. (1999) A DNA damage repair mechanism is involved in the origin of chromosomal translocations t(4;11) in primary leukemic cells. *Oncogene* 18:4663-4671
133. van Dongen JJM, Macintyre EA, Gabert JA, Delabesse E, Rossi V, Saglio E, Gottardi E, Rambaldi A, Dotti G, **Griesinger F.**, Parreira A, Gameiro P, Gonzalez Diaz M, Malec M, Langerak AW, San Miguel JF, Biondi A. (1999) Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. *Leukemia* 13:1901-1928
134. Peters AM, Kohlfink D, Martin H, **Griesinger F.**, Wörmann B, Gahr M, Roesler J (1999) Defective apoptosis due to a point mutation in the death domain of CD95 associated with autoimmune lymphoproliferative syndrome, T-cell lymphoma and Hodgkin's disease. *Exp Hematol* 27:868-874
135. Behr TM, Wörmann B, Gramatzki M, Riggert J, Gratz S, Behe M, **Griesinger F.**, Sharkey RM, Kolb HJ, Hiddemann W, Goldenberg DM, Becker W. (1999) Low vs high dose radioimmunotherapy with humanized anti-CD22 or chimeric anti CD20 antibodies in a broad spectrum of B-cell associated malignancies. *Clin Cancer Res.* 5: 3304S-3314S
136. Schnittger S, Wörmann B, Hiddemann W, **Griesinger F.** (1998) Partial tandem duplications of the MLL gene are detectable in peripheral blood and bone marrow of nearly all healthy donors. *Blood* 92: 1728-1734

137. Herse B, Dalichau H, Wörmann B, Hemmerlein B, Schmidberger H, Hess CF, Hannemann P, Criege CP, Hiddemann W, **Griesinger F.** (1998) Outpatient induction chemotherapy with docetaxel/carboplatin in advanced non-small-cell lung cancer (NSCLC). *Thorac Cardiovasc Surg* 46:298-302
138. Buske C, Becker D, Feuring-Buske M, Hannig H, **Griesinger F.**, Schneider E-M, Hiddemann W, Woermann B. (1998) TGF beta and its complex in leukemic B-cell precursors. *Exp Hematol* 26:1155-1161
139. **Griesinger F.**, Elfers H, Ludwig W-D, Falk M, Rieder H, Harbott J, Lampert F, Heinze B, Hoelzer D, Thiel E, Riehm H, Wörmann B, Fonatsch C, Hiddemann W. (1994) Detection of HRX-FEL fusion transcripts in pre-pre-B-ALL with and without cytogenetic demonstration of t(4;11). *Leukemia*; 8:542-548.
140. **Griesinger F.**, Grümayer ER, Van Ness B, Kersey JH. (1992) Rearrangement and diversification of T cell receptor delta genes in acute lymphoblastic leukemia. *Leukemia*, 6:1054-1062.
141. **Griesinger F.**, Jansen B, Kersey JH (1991). Differentiation in mature T lymphoid leukemia cells is unstable and reversible to myeloid cells, without the involvement of a common stem cell. *J Immunol*, 147:333-341.
142. **Griesinger F.**, Younger PW, Kersey JH. (1991) Organization of the T-cell receptor alpha/delta locus by deletional analysis of acute lymphoblastic leukemias and leukemic cell lines. *Leukemia*, 5: 673-679.
143. Grümayer ER, **Griesinger F.**, Hummel DS, Brunning RD, Kersey JH. (1991) Identification of novel B-lineage cells in human fetal bone marrow which coexpress CD7. *Blood*, 77: 64-68.
144. **Griesinger F.**, Bergmann L, Barot-Ciorbaru R, Mitrou PS. (1990) Intrinsic B-lymphocyte defect in patients with untreated Hodgkin's disease. *Clin Immunol Immunother*, 32:256-260.
145. LeBien TW, Elstrom RL, Kersey JH, **Griesinger F.** (1990) Analysis of immunoglobulin and T-cell-receptor gene rearrangements in human fetal bone marrow B lineage cells. *Blood*, 76:1196-1200.
146. **Griesinger F.**, Arthur DC, Brunning R, Parkin JL, Ochoa AC, Miller WJ, Greenberg JM, Hurvitz C, Kersey JH. (1989) Mature T-lineage leukemia with growth factor induced multi-lineage differentiation. *J. Exp. Med.* 169:1101-1120.
147. **Griesinger F.**, Greenberg JM, Kersey JH. (1989) T-cell receptor gamma and delta rearrangements in hematological malignancies: relationship to lymphoid differentiation. *J. Clin. Invest.* 84: 506-516.
148. Ganser A, Carlo-Stella C, Bartram CR, Böhm T, Heil G, Henglein B, Müller H, Raghavachar AN., von Briesen H, **Griesinger F.**, Völkers B, Rübsamen-Waigman H, Helm EB, Hoelzer D. (1988) Establishment of two Epstein-Barr virus negative Burkitt cell lines from a patient with AIDS and B-cell lymphoma. *Blood* 73:31.

Reviews:

1. **Griesinger F.**: Systemtherapie bei molekularen Subgruppen des nicht-kleinzelligen Lungenkarzinoms. *Trillium Krebs und Medizin* 2014
2. **Griesinger F.**: Klinische Studien in der Ära der molekular stratifizierten Therapie . *Forum Onkologie* 2014
3. **Griesinger F.**: Review Artikel Butts et al. *Lancet Oncology* 2014. *Focus Oncology* 2014
4. **Griesinger F.**: Aktuelle Systemtherapie des metastasierten Lungenkarzinoms *Journal Onkologie* 9/12

Book Chapters:

1. **Griesinger F.:** Nausea und Emesis in der Onkologie:Kapitel Nausea und Emesis bei Lungenkarzinomen. Unimed Verlag, Ed. F. Lordick, 2016
2. **Griesinger F.:** Nausea und Emesis in der Onkologie:Kapitel Nausea und Emesis bei Lungenkarzinomen. Unimed Verlag, Ed. F. Lordick, 2014
3. **Griesinger F.,** Biology and Detection of t(4;11) ALL. in Haematology and Blood Transfusion: Acute Leukemias VI. Büchner T, Hiddemann W, Wörmann B, Schellong G, Ritter J, Creutzig W (Eds.), 1997, pp82-89
4. **Griesinger F.,** Kaib, N, Könemann S, Maecker B, Prio-Noack M, Falk M, Ritter J, Büchner T, Hiddemann W, Terstappen LWMM, Wörmann B. Characterization of normal and leukemia lymphohematopoietic precursor cells (LHPC) by three-color-flow-cytometry and detection of clone-specific leukemia-associated T-cell-receptor d rearrangements.in Haematology and Blood Transfusion: Acute Leukemias VI. Büchner T, Hiddemann W, Wörmann B, Schellong G, Ritter J, Creutzig W (Eds.), 1997, pp224-231
5. **Griesinger F.,** Jahn T, Elfers H, Ludwig W-D, Falk M, Rieder H, Harbott J, Lampert F, Heinze B, Hoelzer D, Thiel E, Riehm H, Wörmann B, Fonatsch C, Hiddemann W. Heterogeneity of HRX-FEL fusion transcripts in adult and pediatric t(4;11) ALL.in Haematology and Blood Transfusion: Acute Leukemias V, Hiddemann W, Büchner T, Wörmann B, Ritter J, Creutzig U, Keating MJ, Plunkett W (Eds), 1996, pp. 15-24.
6. Wörmann B, Grove D, Falk M, Könemann, S., Markloff Y, Toepker S, Heyll A, Aul C, Ritter J, Büchner T, Hiddemann W, Terstappen LWMM, **Griesinger F.,** Distrubution of cells with a „stem cell like“ immunophenotype in acute leukemia. in Haematology and Blood Transfusion: Acute Leukemias V, Hiddemann W, Büchner T, Wörmann B, Ritter J, Creutzig U, Keating MJ, Plunkett W (Eds), 1996, pp. 506-513.